Background and Mechanism

5-Amino-1MQ operates as an inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme central to regulating nicotinamide metabolism and intracellular NAD+ levels. NNMT is expressed abundantly in adipose tissue, where it has been associated with fat cell size and lipid storage dynamics. By inhibiting NNMT, 5-Amino-1MQ has been observed in models to elevate NAD+, activate downstream metabolic regulators, and support pathways that encourage higher energy expenditure and reduced adiposity.

Chemical Characteristics

Research Highlights

1. Weight and Adiposity in Animal Studies

– Preclinical work in obese murine models suggests that encapsulated 5-Amino-1MQ administration led to decreases in overall body weight and reductions in white adipose mass.
– Importantly, these changes were observed without significant reductions in food consumption, pointing to enhanced energy metabolism rather than appetite suppression as the primary mechanism.

2. NAD+ and Mitochondrial Function

– NNMT inhibition via 5-Amino-1MQ was associated with higher NAD+ levels, thereby influencing sirtuin activation and mitochondrial function.
– These metabolic shifts are thought to play a role in improved energy turnover and lipid utilization in adipose tissue.

3. Benefits of Encapsulation for Research

– Capsules offer researchers precise dosing control and improved consistency across studies.
– Encapsulation may also reduce compound degradation during storage, offering extended shelf life compared to reconstituted solutions.
– The capsule format minimizes handling steps, which can simplify study design in metabolic and obesity-related research models.

General Specifications (Research Grade)

Form: Capsules (for research use only)
Target: Nicotinamide N-methyltransferase (NNMT) inhibitor
Suggested Application: Preclinical or in vitro metabolic studies
Storage: Preserve in a cool, dry environment away from direct light

References

1. Kraus D, Yang Q, Kong D, Banks AS, Zhang L, Rodgers JT, Pirinen E, Pulinilkunnil TC, Gong F, Wang YC, Cen Y, Sauve AA, Asara JM, Peroni OD, Monia BP, Bhanot S, Alhonen L, Puigserver P, Kahn BB. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014;508(7495):258–262. doi:10.1038/nature13198.

2. Ulanovskaya OA, Zuhl AM, Cravatt BF. NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink. Nature Chemical Biology. 2013;9:300–306. doi:10.1038/nchembio.1204.

3. Kannt A, Rajagopal S, Kadnur SV, Suresh J, Bhamidipati RK, Swaminathan S, Hallur MS, Kristam R, Pieper MP. Novel small molecule inhibitors of nicotinamide N-methyltransferase (NNMT). Bioorganic & Medicinal Chemistry Letters. 2018;28(17): 3071–3075. doi:10.1016/j.bmcl.2018.07.009. PMC5826726.

4. van der Vaart A, et al. Reduced calorie diet combined with NNMT inhibition establishes a metabolic memory. Scientific Reports. 2021;11:24840. doi:10.1038/s41598-021-03670-5.

5. Liu H, Liu D, Zhao X, Wright M, Guo H, Deng Y, Guo H. Roles of Nicotinamide N-Methyltransferase in Obesity and Type 2 Diabetes. International Journal of Molecular Sciences. 2021;22(15): 8199. doi:10.3390/ijms22158199. PMC8337113.

6. Alston CL, et al. Nicotinamide N-methyltransferase: a novel therapeutic target. Drug Discovery Today. 2021;26(12): 2767–2778. doi:10.1016/j.drudis.2021.07.009.

7.Frontiers in Pharmacology. NNMT inhibition and metabolic regulation. 2024. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1410479/full

NOTICE OF COMPLIANCE

The mission of BioGenix Peptides™ is to provide researchers with the highest-quality, Ultra-Pure Series™ compounds to help unlock the full potential of this evolving field. With precision, purity, and scientific integrity at the core of our operations, BioGenix Peptides™ is dedicated to supporting responsible exploration and discovery

Products from BioGenix Peptides™ are not intended for human consumption. They are supplied exclusively for in-vitro and pre-clinical research purposes.

By purchasing or using these products, the Customer accepts full responsibility for their handling and use, and agrees to indemnify and hold BioGenix Peptides™ harmless from any claims resulting from misuse.